key: cord-1051067-a86yn2xf authors: Belkacemi, Yazid; Grellier, Noemie; Ghith, Sahar; Debbi, Kamel; Coraggio, Gabriele; Bounedjar, Adda; Samlali, Redouane; Tsoutsou, Pauletta G.; Ozsahin, Mahmut; Chauvet, Marie-Pierre; Turkan, Sedat; Boussen, Hamouda; Kuten, Abraham; Tesanovic, Dusanka; Errihani, Hassan; Benna, Farouk; Bouzid, Kamel; Idbaih, Ahmed; Mokhtari, Karima; Popovic, Lazar; Spano, Jean-Philippe; Lotz, Jean-Pierre; Cherif, Aziz; To, Hahn; Kovcin, Vladimir; Arsovski, Oliver; Beslija, Semir; Dzodic, Radan; Markovic, Ivan; Vasovic, Suzana; Stamatovic, Liljana; Radosavljevic, Davorin; Radulovic, Sinisa; Vrbanec, Damir; Sahraoui, Souha; Vasev, Nino; Stojkovski, Igor; Risteski, Milan; Freixa, Salvador Villà; Krengli, Marco; Radosevic, Nina; Mustacchi, Giorgio; Filipovic, Mladen; Kerrou, Khaldoun; Taghian, Alphonse G.; Todorovic, Vladimir; Geara, Fady; Gligorov, Joseph title: A review of the international early recommendations for departments organization and cancer management priorities during the global COVID-19 pandemic: applicability in low- and middle-income countries date: 2020-06-08 journal: Eur J Cancer DOI: 10.1016/j.ejca.2020.05.015 sha: cdc481a04c53c073c997037afdf453705a22714e doc_id: 1051067 cord_uid: a86yn2xf Coronavirus disease 2019 (COVID-19) is an infectious disease caused by a new virus that has never been identified in humans before. COVID-19 caused at the time of writing of this article, 2.5 million cases of infections in 193 countries with 165,000 deaths, including two-third in Europe. In this context, Oncology Departments of the affected countries had to adapt quickly their health system care and establish new organizations and priorities. Thus, numerous recommendations and therapeutic options have been reported to optimize therapy delivery to patients with chronic disease and cancer. Obviously, while these cancer care recommendations are immediately applicable in Europe, they may not be applicable in certain emerging and low- and middle-income countries (LMICs). In this review, we aimed to summarize these international guidelines in accordance with cancer types, making a synthesis for daily practice to protect patients, staff and tailor anti-cancer therapy delivery taking into account patients/tumour criteria and tools availability. Thus, we will discuss their applicability in the LMICs with different organizations, limited means and different constraints. Coronavirus disease 2019 (COVID- 19) is an infectious disease caused by a new virus that has never been identified in humans before. This virus causes respiratory illness with symptoms like cough, fever and, in most severe cases, pneumonia. At the time of writing of this article, 2.5 million cases of infections have been reported in 193 countries with 165,000 deaths, including Twothird in Europe in accordance with the applied case definitions and testing strategies in the affected countries. This pandemic surprised the whole world by its contagiousness, with a high speed of diffusion in all subpopulations and its violence in terms of deaths. The Oncology Departments of the affected countries had to adapt quickly and establish new organizations with a practical definition of priorities. Thus, numerous recommendations and therapeutic options have been developed to allow the optimization of departments' organization and function in order to provide and continue to deliver optimal therapy to all patients with cancer. In these exceptional circumstances, many groups and scientific societies have made practical recommendations. In Europe, the first recommendations concerned mainly the way of protecting patients with cancer [1] . Since then, many guidelines have been proposed for different types of cancers. Obviously, this type of recommendation immediately applicable in Europe may not be applicable in certain emerging countries or low-and middle-income countries (LMICs). Thus, it seemed fundamental to us to summarize these international guidelines according to cancer types and to make a synthesis for daily practice. In addition, we aimed to discuss their applicability in the LMICs with different organizations, limited means and different constraints. To collect the French data, we sent an e-mail to the French Oncology Societies that had not reported guidelines for COVID-19 crisis between March 1st and April 30th. The responses are summarized in Table 1 . For the international literature data, a search in PubMed was performed using the following key words: 'COVID-19 and oncology', 'COVID-19 and cancer', 'COVID-19 and radiotherapy' (RT), 'COVID-19 and guidelines for cancer', 'COVID-19 and recommendations for cancer'. All abstracts and articles in English were collected. Articles in Chinese without English abstracts were not included in the review. In Fig. 1 , we summarized the literature search and references that are included in this review. In summary, articles related to oncology guidelines and organization were selected based on the search using the following keywords: -For 'COVID-19 and oncology': Among the 78 articles, 9 were related to either guidelines/recommendations (n Z 5) [1e5] or medical and health system organization (n Z 4) [6e9]. -For 'COVID-19 and cancer': Among the 134 articles, 12 were related to either guidelines/recommendations (n Z 6) [10e15] or medical and health system organization (n Z 6) [16e22]. -For the last 3 key words, namely 'COVID-19 and radiotherapy' (n Z 13) [23e29], 'COVID-19 and guidelines for cancer' and 'COVID-19 and recommendations for cancer', the 21 additional references found were redundant and were found with the first two searches (Fig. 1 ). All recommendations, including guidelines for RT practice (23) (24) (25) (26) (27) (28) (29) , have been finally summarized in tables and discussed via e-mails with the AROME and TRONE networks members regarding their applicability in LMICs. (Table 2) Patients with cancer are more susceptible to infection than individuals without cancer because of the immunosuppressive effect induced by and anti-cancer therapy. In the context of a global public health emergency related to the emergence of COVID-19, it is essential to protect patients and staff to ensure continuity of care. Thus, a major reorganization of our departments was needed to adapt the resources for oncology care maintenance to ensure timely and proportionate implementation of contingency plans that balance risks and protect patients and healthcare workers during the infections rise period. Moreover, the departments reorganization must take into account specifics of the specialities involved in the management of patients with cancer. For surgery, two situations are to be distinguished: patients having undergone surgery just before the COVID-19 outbreak and patients whose surgery is already or must be planned during this period. In the first case, it is reported that COVID-19epositive patients are likely to be at higher risk of clinically severe events than those who did not have surgery. Thus, protective measures must be reinforced and their visits to the department limited. The emergency for adjuvant treatments delivery should be discussed on a case-by-case basis. For scheduled surgery, the discussion will focus on the delayed interventions, taking into account the benefit/ risk ratio for each patient. In Table 2 some recommendations are presented, from our group (AROME) and others, regarding the prioritization of urgent surgeries and the need to work with the hospital to ensure that adequate supplies (PPE, staffing, and bed capacity) will be available for nonelective, time-sensitive surgeries. Delayed oncologic surgeries may lead to disease progressions and result in tumours that are no longer resectable, leading to worse survival outcomes. Thus, all decisions for delayed surgery AE shift to neoadjuvant therapies should be taken in the frame of multidisciplinary board meetings. In RT departments, staff must also be protected against COVID-19 at all times. Weekly or daily team rotation and dedicated routes for positive COVID-19 patients taken in dedicated time slots with full protection of staff is a prerequisite to reduce the risk to staff and noninfected patients. Tables 2 and 3 show the main reported global and specific recommendations. In Table 3 , we present the main recommendations for workers in RT departments and staff organization, in accordance with available human resources. In addition, scenarios taking into account the reduction in the number of workers in case of COVID-19 infection have been proposed to ensure treatment with the required quality and safety. For patients, a distinction must be made between patients who have started treatment and those who have not yet started irradiation. For the first, finishing treatment is a priority, either following initial planned fractionation schedules or after plan recalculation to shorten treatment duration. For the weekly visits, telemedicine and phone calls could be advocated to limit the time spent in the hospital every day. For COVID-19epositive patients, dedicated areas, separate exit/entrance and dedicated time slots have to be planned. For patients who have not started RT yet, priorities should be also fixed as per tumour sites, adjuvant or neoadjuvant settings, the possibility of delaying irradiation in settings where primary chemotherapy or endocrine therapy could be administrated. These situations will be discussed in the next section. As for other departments, dedicated areas, specific exits/ entrance and a limited number of patients in the waiting rooms are recommended to limit contacts between infected and non-infected patients. To ensure minimal presence in the hospital, some regimens can be altered to minimize infusion visits or a switch to oral drugs when possible. During treatments, systematic screening before appointments is recommended by the majority of experts. For patients already in deep remission (stable for more than 6e12 months), stopping or delaying treatment may be an option. A temporary break could be an option for patients with slowly evolving metastases. For all patients on active anti-cancer therapy, we need to remain vigilant for COVID-19 symptoms. Their therapy should be planned in a dedicated area. Changes in management strategy and therapy in accordance with type of cancer (Table 4 ). The medical complexity of head and neck cancer management may lead to prolonged delays that worsen treatment outcomes. Therefore, those caring for patients with head and neck cancer must take action to reduce these negative impacts as the country rallies to overcome the challenges posed by this pandemic [24] . Thus, therapeutic adaptation possibilities reported by the French groups are based mainly on expert opinion [30,31]. Thus, in daily practice, any adaptation must be discussed with the patient and in the frame of multidisciplinary board meetings. For surgery community, the aim is to minimize the risk of care opportunity loss for patients and to anticipate the increased number of cancer patients to be treated at the end of the pandemic, taking into account the degree of urgency, the difficulty of the surgery, the risk of contaminating the caregivers (tracheotomy) and the local situation (whether or not the hospital and intensive care departments are overstretched) [30,31]. All indications for combined chemoradiotherapy must be maintained, as well as the usual delays between diagnosis and RT ( 4 weeks) or between surgery and RT (6e8 weeks). Fractionation must be optimized: favour hypofractionation (early-stage larynx, elderly or comorbid patients) and simultaneous integrated boost [30]. Following the ESTRO (European society of therapeutic radiation oncology)-ASTRO (American society of therapeutic radiaion oncology) consensus statement [32] and the French recommendations [33] , we need to distinguish recommendations according to pathology and stage of the disease. For early nonesmall-cell lung cancer, surgery could be delayed up to 6 weeks for stage I II, N0 disease. Another alternative approach is to deliver stereotactic RT with a limited number of fractions (1 to 3). In the post-operative setting, patients undergoing treatment have to complete their program. For adjuvant RT, given the uncertainty about its impact in this context, it is not recommended to initiate RT for patients with N2 disease. In locally advanced nonesmall-cell lung cancer, patients are more at risk of developing severe respiratory acute complications requiring intensive care. Thus, only patients who are already undergoing therapy should complete their program while initiation of RT in new patients is discussed in the frame of multidisciplinary bord meetiings. For patients undergoing chemotherapy, carboplatin is preferred over cisplatin for its rapidity of administration and its lower toxicity. The administration of durvalumab must be carried out if the safety conditions are reasonable, by adapting the treatment regimen [33] . The American Society of Breast Surgeons (ASBS) [34], the French Saint Paul-de-Vence (SPDV) group [35] and the international RT network [3] reported their recommendations in March. The ASBS recommended breaking into three priority categories based on patient conditions, ranging from immediately life-threatening conditions to patients stable enough that services can be delayed for the duration of the COVID-19 pandemic. In the SPDV conception, different scenarios were detailed. In summary, for post-operative patients and those on follow-up telemedicine is recommended. Interventions for biopsies in abnormal mammograms, neoadjuvant patients finishing treatment, hormone therapy during 6e12 months for luminal hormone receptor (HR)-positive patients, adjuvant antibody treatment reasonably be curtailed after 7 months instead of 12 months of treatment for HER2-positive and limit reconstructive surgery to expander only are the main recommendations. In addition, more specifically in patients with breast luminal cancer (early or locally advanced) primary endocrine treatment could safely delay surgery up to 3 to 6 months, in a ccoradnce with several published trials. For adjuvant RT, up to 16 weeks of last surgery or chemotherapy with high-risk indications for radiation, such as inflammatory disease, node positive disease, triple negative breast cancer, post-neoadjuvant chemotherapy with residual disease at surgery, young age (<40) with additional high-risk features, are recommended. Patients older than 65e70 y with lower risk stage I HR-positive/HER2-negative cancers and ductal carcinoma in situ (DCIS), adjuvant endocrine therapy can be encouraged to defer/omit radiation without affecting overall survival. Hypofractionated regimens are recommended, including in cases of DCIS, post-mastectomy or nodal RT. The boost is reserved for high-risk patients, and SIB or hypofractionation is to be preferred [3, 22, 29, 35] . Since the beginning of March, numerous scientific societies and research groups provided recommendations for cervical, endometrial and ovarian cancer [36, 37] . In summary, for cervical cancer, it has been suggested that the value of lymph node staging surgeries must be reviewed on a case-by-case basis in accordance with comorbidities, imaging results and stage of disease. For therapy, the recommendation is to omit any changes in radiochemotherapy regimens or interrupt or postpone RT that could lead to tumour response reduction. After concomitant radiochemotherapy, surgery should not be systematic in cases of complete response. In endometrial cancer, recommendations are in accordance with the stage of disease [36] . Surgery remains the standard of care for early-stage disease. The minimally invasive laparoscopic approach, robotassisted (or not) is the preferred approach. For low and intermediate pre-operative European society of medical oncology (ESMO) risk, total hysterectomy with bilateral ovariectomy associated with a sentinel node procedure should be preferred. It is lawful to consider postponing surgery by 1e2 months in low-risk endometrial cancers. For high ESMO risks involving staging by pelvic and lumbo-aortic nodal dissection, it seems recommended to favour the Memorial Sloan Kettering Cancer Center (MSKCC) algorithm, associating positrons emission tomography -computed tomography (PET-CT) and sentinel node biopsy procedure to omit nodal dissection which increases the risk of pre-and post-operative complications. For ovarian cancers, recommendations are as per the stage of disease. For early-stage ovarian cancer, surgery may be postponed by 1e2 months, whereas for advanced disease, neoadjuvant chemotherapy or primary 'debulking' surgery should be considered. In cases of neoadjuvant chemotherapy, additional cycles up to 6 could be considered before surgery [36] . For vulvo-vaginal cancers, the main messages consist of delaying surgery by 1e2 months and indicate chemoradiation in locally advanced cases, whereas PET-CT for staging should be favoured to delay lymph node dissection. Recommendations concerned mainly prostate, bladder and kidney cancers. In summary, the French recommendations [12, 38] for prostate cancer are oriented towards delaying all RT planning by 3e6 months. During this period, ADT administration is recommended in intermediate and high-risk patients. For RT, schedules should be hypofractionated if RT is started during the COVID-19 period [39, 40] . For low-risk patients, surgery could be delayed in favour of active surveillance. Moreover, surgery should not be delayed more than two months in high-risk and locally advanced patients [12] . This will be considered in accordance with the availability of operating rooms and the post-operative complications risk. In patients with bladder cancer, surgery should not be delayed more than three months in the majority of cases. When RT is indicated, it should be hypofractionated. Primary chemotherapy and number of cycles should be discussed on a case-by-case basis. If surgery is preferred, a maximum of three months after diagnosis is proposed [12] . For the kidneys, beside locally advanced and thrombosis situations, surgery has to be delayed after confirmation in the tumour board [12] . In summary, surgery could be postponed by three months for gastrointestinal (GI) cancers when other therapies are indicated. All decisions should be taken in accordance with the stage of the disease and the risk of spread in case of delaying optimal therapy [25] . Oesophagus cancer should be treated whenever possible with RT and concomitant carboplatin and taxol. In the neoadjuvant setting or salvage therapy, surgery could be delayed up to three months [40, 41] . Detailed RT recommendations, including definitive combined radiochemotherapy and fractionation have been reported by Jones et al. [26] . They also suggested that as the impact of RT on disease severity in patients with a diagnosis of COVID-19 is unknown and it may be appropriate to avoid RT in such patients. Surgery for rectal cancer should be delayed up to three months [40] and neoadjuvant treatment for new patients should be carried out with the short-course scheme [40, 42] , reserving the classical CAP50 therapy. The watch and wait attitude is possible for patients with complete response after standard chemo-RT [40, 43, 44] . In anal canal carcinomas, chemo-RT capecitabine should replace 5-FUþ/-mitomycin C [40, 45] . Brachytherapy, if indicated, could be delayed [39] . For pancreatic and other GI cancers, ESMO guidelines defined high priorities for surgery and systemic therapy [46, 47] . All resectable cancers and borderline patients who are not fit for neoadjuvant chemotherapy should be considered as high priority. In locally advanced disease, initiation or completion of neoadjuvant chemotherapy when already started or patients included in clinical trials should be also considered as a high priority [47] . This review aims to summarize some national/international guidelines and literature regarding the organization of patient management and specific recommendations by tumour sites. Indeed, outbreaks of COVID-19 disease may result in the interruption of medical care provided to patients with cancer and induce undertreatment in addition to the risk of infection and death from COVID-19. Early data from China and Italy suggest that patients with cancer may be at higher risk of contracting COVID-19, particularly when multiple visits are needed, and also developing more severe forms of the disease [48, 49] . One prospective study on 1590 patients pointed out the higher incidence of COVID-19 in patients with cancer [49] . In addition, patients with cancer seem to be at a greater risk of ventilation need and death [50,51]. Thus, preventing patients with cancer from being exposed to COVID-19 is a critical public health priority that needs an important effort in terms of staff and department organization and patient screening to adapt therapy delay and management despite COVID-19 infection risk. The benefit risk/ratio is a key point for all newly diagnosed cancers, as delaying treatment is not recommended if, at all, avoidable [28, 52] . In LMICs the problem of delay in diagnosis already exists. So the fear with the COVID-19 pandemic is to see an increase in the number of patients with locally advanced cancers who do not receive treatment in time. In certain countries, with the screening program being stopped during the pandemic, locally advanced forms may resurface in local epidemiology if screening remains suspended for a long time. For head and neck cancers for example, a panel from ASTRO and ESTRO have published statement with two pandemic scenarios: early (risk mitigation) and late (severely reduced RT resources) and treatment recommendations for five head and neck cases. There was agreement (or strong agreement) across a number of practice areas including: treatment prioritization, whether to delay initiation or interrupt RT [27] . In the last three months, a number of scientific societies, oncology groups and experts' networks have suggested that all efforts should be made to prevent patients with cancer from being exposed to COVID-19. They also proposed several recommendations for urgent new organization in oncology departments with possible patient selection, treatments and schedules tailored in accordance with patients and tumour criteria, so as to continue to provide adequate strategy for the majority of patients [1, 2, 7, 11, 16] . In accordance with the local health system organization and tools availability, different approaches have been undertaken by cancer centres and oncologists in countries with early epidemics, in response to the risk of infection, as well as strain on health systems. The main proposals are summarized in Tables 2 and 3 . They are as follows: (i) Minimizing the risk of exposure for patients (with a clear policy of screening before appointments) and staff (with daily temperature screening) to protect the immune compromised patients. (ii) Department reorganization with minimizing patient turnover times ('fast track' area) and number of visits to the hospital. Use of telemedicine and phone calls for postponed appointments and non-urgent surgeries or other treatments [53, 54] . (iii) Delaying locoregional therapy data to reduce risk of COVID-19 in patients with cancer are limited. The American College of Surgeons recommends balancing the risk of delay of an elective surgery with the potential likelihood for a post-operative need for respirator utilization [54] . In addition, patients with a history of surgical resection may have continued immunosuppression or other prolonged effects of surgery, which can contribute to COVID-19 risk [55] . (iv) Shortening RT duration and plan recalculations for hypofractionated schedules have been proposed in accordance with the type of cancer and curative or palliative intent situations. In some cases (e.g., low-risk breast and prostate cancers), endocrine therapy is advocated to delay RT by 2e4 months [3, 38, 39] . (v) Switching patients from intravenous to oral therapies to limit the number of inpatient visits has been recommended in France [1] and Italy [52] . In all cases, delaying systemic therapy is not recommended if at all avoidable [52] . For patients already in deep remission (stable for more than 6e12 months), stopping treatment may be an option [1, 2, 35] . The vast majority of the published recommendations for department organization, staff and patients' appointments/visits are quite feasible in the majority of LMICS. At times, there may be complex geographic situations, unavailability of equipment or means of communication (telemedicine) and staff which can negatively impact the situation. The selection of patients for whom care can be deferred becomes a major issue in the organizational management of the weeks in which the contagiousness to COVID-19 is high. However, the definition of priorities can be complicated to do in certain LMICs. For example, the NICE recommendation says that during COVID-19 pandemic 'use RT only id unavoidable' [28] . This could be in agreement with the availability of resources and means in LMICs unlike others [28e32] are more precise in terms of patients' selection that takes into account cancer type and disease stage to not compromise the prognosis. Table 4 summarizes the main recommendations by tumour sites. There is mainly a deal between avoiding COVID-19 contamination for patients without making them lose chances of cure due to deferring or suspending standard effective treatment. Even if limited evidence exists on the modification of treatment plans to reduce the risk of COVID-19 in patients with cancer, these recommendations are an important support for many oncologists to help with the decision. Adapted to the local situation, they can also serve as a basis for decisions in LMICs. However, we must note the fact that, in addition to the limited means in some countries, the local epidemiological context can limit these recommendations applicability. One example is combined radio chemotherapy for oesophageal cancers. In case of unavailable modern techniques in these countries that could ovoid significantly organ at risk exposure, ovoiding RT has been suggested as an option as the disease severity expected in patients with a diagnosis of COVID-19 is unknown [26] . For surgery scheduling, the American College of Surgeons recommends balancing the risk of delay of an elective surgery with the potential likelihood for postoperative ICU or respirator use [54] . Presumably, in certain LMICs, oncological surgery continues to be carried out in general surgery departments which are very widely transformed into UCI during the COVID-19 crisis. Thus, this transformation necessary to take care of patients with COVID-19 with respiratory distress directly impacts the cancellation of oncological surgery. Whatever the type of cancer, the consensus is to postpone surgery. The most obvious cases concern those who benefit from screening, such as breast and prostate cancer. The recommended delay can go up to 2e3 months. However, patients' selection for delaying surgery is a crucial point, as delayed oncologic surgeries may lead to disease progression and result in tumours that are no longer resectable, leading to worse survival outcomes [52] . For locally advanced and high-risk patients, neoadjuvant therapies represent a solution before undergoing surgery in breast and some GI cancers [12, 38] . The dilemma in this case is to weigh the risk/ benefit ratio of treating patients optimally during the COVID-19 period with the consequences of immunosuppression [55, 56] and repeated visits to the hospital to receive RT when it is indicated for combined therapy. The delay between the end of pre-operative treatment and surgery can also be lengthened in many cases, such as rectal [43] , endometrial [36] and bladder cancer [12, 38] . In addition, prior RT, the primary treatment, can constitute a "waiting" solution during the COVID-19 period. The recommendations are fairly unanimous for high-risk and locally advanced prostate cancers [12, 38, 39] . Indeed, as the radiohormonotherapy trials of prostate cancer have all used schemes with a primary hormone therapy between 2 and 6 months before RT, it is easier to defer the RT (up to 6 months) without any prejudice for the patient [38, 39] . Recently, Zaorsky et al. [23] have to establish recommendations and a framework by which to evaluate prostate RT management decisions. They concluded that the Remote visits, and Avoidance, Deferment, and Shortening of RT framework can be applied to prostate cancers and other disease sites to help with decision-making in the COVID-19 pandemic. This concept could applicable in LMICs with however some specificities regarding local situations of health care and means. For breast cancer, the data are less robust for primary endocrine therapy while 'waiting' for RT. However, the consensus recommends in many situations to postpone or even omit RT in elderly patients with low risk, as no evidence of impact on survival has been demonstrated in this subset of patients [35] . RT hypofractionation, already largely used in LMICs, is systematically recommended in the adjuvant setting without chemotherapy. A recent report from USA has pointed out the evidence-based guidelines for omitting or abbreviating breast cancer RT, where appropriate, in an effort to mitigate risk to patients and optimize resource use [29] . In breast and prostate cancer, high evidence of equivalence between standard and hypofractionation has been demonstrated in the literature. However, in prostate and breast cancer, this is generally true only for limited irradiation volume in patients without extended nodal RT. Large volume of lung RT could increase the risk of lung damage if the patient became infected by COVID-19 during RT and developed severe respiratory acute syndrome [57] . For systemic therapies, there is currently no evidence to support changing chemotherapy and immunotherapy regimens. In addition, delaying treatment is not recommended if at all avoidable [52] . However, some regimens can be altered to minimize infusion visits. fFor all cytotoxic regimens, dose intensity is important and multiple studies report poorer survival in cases of dose intensity reduction. In the surgical consensuses, the option of an increased number of cycles allowing a surgery delay of 2e6 weeks is advocated [12, 33] . However, this should be carried out with caution regarding treatment efficacy and its potential toxicity. In cases of systemic therapy maintenance, switching IV to oral therapies largely available in LMICs, is mostly recommended to limit the number in-patient visits to the hospital. For patients already in complete remission, stopping or delaying treatment may be an option. The use of systemic treatments is not contraindicated during the COVID-19 pandemic period. However, given the risk of possible immunosuppression, it is important to discuss the indications and to prioritize the treatment strategies in accoradance with the benefit-risk ratio as this has been underlined in the various reference systems cited previously [46, 47, 52] . The COVID-19 pandemic has and will have a major impact on the organization of healthcare systems. While novel vaccines and drugs that target SARS-CoV-2 are under development, the challenge for oncology community is to continue to provide the best therapy to all patients. It will be crucial to consider the benefit risk ratio for optimal anti-cancer therapy (to minimize the risk of care opportunity loss for patients) and minimize COVID-19 contaminations during therapy that may interrupt or delay therapy, and thus, compromise patients' outcome. Several recommendations published from the early period of the crisis have helped for urgent new organization in oncology departments with possible patient selection, treatments and schedules tailored according to patients and tumour criteria. In LMICs, the challenge is to define strategies to try mitigating the deleterious effect of COVID-19 pandemic on cancer care. These negative effects will be probably amplified due to (i) epidemiology of cancer diagnosed in more advanced stages in these countries, (ii) limited means for diagnostic and treatment that will delay cancers management; (iii) the need to manage COVID-19 patients in limited number of centres that will impose delay for cancer therapy and (iv) the economic impact of the COVID-19 pandemic on health system priorities and investment in oncology. Of note, the vast majority of these recommendations for department organization, are quite feasible in the majority of LMICs where the context for cancers patients is related multiple parameters such as: late diagnosis, long waiting lists for therapy and the lack of therapeutic innovations due to the economic situation which may be worsened by the COVI-19 pandemic. None. A.I. declares the following relevant financial activities outside the submitted work: has received Grants from Transgene, Sanofi, Air Liquide, Nutritheragene; has received travel funding from Leo Pharma; Grant research support and travel funding from Carthera. J.G. declare the following financial personnal fees for activities outside the submitted work or served as consultant or advisory board/ has received symposium and travel funding from: Roche-Genentech, Novartis, Onxeo, Dachii Sankyo, MSD, Isai, Genomic Health, Ipsen, Macrogenics, Pfizer, Mylan, Lilly, Immunomedics, Sandoz. J.-P.S. declares the following financial personnal fees for activities outside the submitted work or served as consultant or advisory board/ has received Symposium and travel funding from: MSD, Lilly, Roche, Mylan, Pfizer, PF Oncology, LeoPharma, Novartis, Biogaran, Astra Zeneca, Gilead, BMS. All the other authors have no conflict of interest to declare. The official French guidelines to protect patients with cancer against SARS-CoV-2 infection A practical approach to the management of cancer patients during the novel coronavirus disease 2019 (COVID-19) pandemic: an international collaborative group International guidelines on radiation therapy for breast cancer during the COVID-19 pandemic COVID-19 global pandemic: options for management of gynecologic cancers Chinese Medical Association; Chinese Respiratory Oncology Collaboration. Expert recommendations on the management of patients with advanced non-small cell lung cancer during epidemic of COVID-19 Pathways for urology patients during the COVID-19 pandemic Managing oncology services during a major coronavirus outbreak: lessons from the Saudi arabia experience Members of the research urology network (RUN) CVID-19 outbreack in northern Italy : first practical indications fro radiotherapy Safety recommendations for evaluation and surgery of the head and neck during the COVID-19 Pandemic Practical strategies against the novel coronavirus and COVID-19-the imminent global threat Le Comité de Cancérologie de l'Association Française d'Urologie (CCAFU). Recommendations CCAFU on the management of cancers of the urogenital system during an epidemic with Coronavirus COVID-19 Guidelines for surgical management of gynaecological cancer during pandemic COVID-19 period -FRAN-COGYN group for the CNGOF Individualized treatment recommendations for lung cancer patients at different stages of treatment during the outbreak of Preliminary recommendations for lung surgery during 2019 novel coronavirus disease (COVID-19) epidemic period Singapore (NCIS). A segregated-team model to maintain cancer care during the COVID-19 outbreak at an academic center in Singapore Cancer, COVID-19 and the precautionary principle: prioritizing treatment during a global pandemic Treatment approach in locally advanced rectal cancer during Coronavirus (COVID-19) pandemic: long course or short course? Coronavirus pandemic and Colorectal surgery: practical advice based on the Italian experience SARS-CoV-2/COVID 19 Infection and solid cancers: synthesis of recommendations for health professionals COVID-19 infection epidemic: the medical management strategies in Heilongjiang Province, China. Crit Care COVID-19 global radiation oncology's targeted response for pandemic preparedness Prostate cancer radiotherapy recommendations in response to COVID-19 Impact of the COVID-19 pandemic on the management of head and neck malignancies Strategy for the practice of digestive and oncological surgery during the Covid-19 epidemic Considerations for the treatment of oesophageal cancer with radiotherapy during the COVID-19 pandemic Practice recommendations for risk-adapted head and neck cancer radiotherapy during the COVID-19 pandemic: an ASTRO-ESTRO consensus statement Covid-19: use radiotherapy only if "unavoidable," says NICE Breast radiotherapy under COVID-19 pandemic resource constraints -approaches to defer or shorten treatment from a Comprehensive Cancer Center in the United States French Society of Otorhinolaryngology, Head and Neck Surgery (SFORL), French Society of Head and Neck Carcinology (SFCCF). French consensus on management of head and neck cancer surgery during COVID-19 pandemic. Eur Ann Otorhinolaryngol Head Neck Dis Practice recommendations for lung cancer radiotherapy during the COVID-19 pandemic: an ESTRO-ASTRO consensus statement On behalf of the French-Language Society of Pulmonology (SPLF) / French-language Oncology Group. Proposals for managing patients with thoracic malignancies during COVID-19 pandemic COVID-19 and people followed for breast cancer: French guidelines for clinical practice of Nice-St Paul de Vence pii: S0007e4551, French Recommendations for the surgical management of gynecological cancers during the COVID-19 pandemic -FRANCOGYN group for the CNGOF Yale radiation oncology Flowchart for COVID-19 e Version Therapeutic options for genitourinary cancers during the epidemic period of COVID-19 Covid-19 epidemic: guidelines issued by the French society of oncology radiotherapy (SFRO) for oncology radiotherapy professionals Strategy for the practice of digestive and oncological surgery during the COVID-19 epidemic COVID-19 epidemic: Proposed alternatives in the management of digestive cancers: A French intergroup clinical point of view Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a propensity-score matched cohort analysis Organ preservation for rectal cancer (GRECCAR 2): a prospective, randomised, open-label, multicenter, phase 3 trial Chemoradiotherapy with capecitabine for locally advanced anal carcinoma: an alternative treatment option ESMO management and treatment adapted recommendations in the COVID-19 era: colorectal cancer ESMO management and treatment adapted recommendations in the COVID-19 era: pancreatic cancer Running a radiation oncology department at the time of coronavirus: an Italian experience Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China Managing COVID-19 in the oncology clinic and avoiding the distraction effect Global telemedicine implementation and integration within health systems to fight the COVID-9 pandemic: a call to action. JMIR Publ Health Surveill Elective case triage guidelines for surgical care The management of the surgical patients during the coronavirus dieases 2019 (COVID-19) pandemic. Surgery Risk of COVID-19 for cancer patients Regional lymph node irradiation in breast cancer may worsen lung damage in COVID-19 positive patients The authors would like to thank Ms Myrna Perlmutter for her help in editing English language for this manuscript.